-The Economic Times NEW DELHI: Getting better is getting cheaper. The new drug price policy, the first after 18 years and expected to fully come into effect over the next six months, will reduce average middle class household spend on medicines by over 20%. For some crucial medicines, savings could be as much as 50% or more. The drug price regulator is crunching numbers to measure the impact of the new pricing...
More »SEARCH RESULT
Total Matching Records found : 120
Santhali women caught between birth and death—sans medical help -Anumeha Yadav
-The Hindu Sundarpahari (Jharkhand): In Santhali villages in Godda, along Jharkhand's border with Bihar, many slanting stone megaliths that mark the community graves are those of young women who died in childbirth in recent years. Tribal families in the hamlets scattered in Sundarpahari and Poreyhat - many of whom speak only Santahli - recount desperate struggles for medical help when young women in their families in advanced stages of pregnancy experienced...
More »Lifestyle diseases to cost India $6 trillion, study estimates -Durgesh Nandan Jha
-The Times of India NEW DELHI: India's march towards being an economically stable nation is threatened not just by global financial issues. Poor health indicators pose an equally big threat. The Harvard School of Public Health has, in a study on economic losses due to non-communicable diseases (NCDs), estimated that the economic burden of these ailments for India will be close to $6.2 trillion for the period 2012-30, a figure that is...
More »Epidemic of Vitamin D shortage puts Indians at high blood pressure risk -Malathy Iyer
-The Times of India MUMBAI: Runny noses and stomach flu aren't the only ills associated with overcast skies. The absence of sunlight hits production of Vitamin D in the body, adversely affecting blood pressure. A recent study in London by an Indian-born researcher has proved beyond doubt that the lower the vitamin level, the higher the BP. Vitamin D is synthesized when the sun's ultraviolet rays fall on the skin. But the...
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »
